article thumbnail

CIOs look beyond ‘Big 3’ cloud providers for AI innovation

CIO Business Intelligence

Having previously run its AI workloads on premises, the clinical-stage biotechnology company chose Vultr Cloud GPU, a GPU-as-a-service that Athos runs on Dells Nvidia-powered HGX H100 PowerEdge servers to train its homegrown AI models and build its AI-powered precision medicine platform aimed at solving auto-immune and cancerous diseases.

Cloud 323
article thumbnail

Nautilus Biotechnology shares surge 50% on news of Amazon investment

GeekWire

Nautilus Biotechnology co-founder Sujal Patel. Shares of Nautilus Biotechnology rose by as much as 50% on Thursday morning after a report revealed that Amazon has taken an equity stake in the newly public Seattle-based company. Nautilus Photo).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Regeneron and auticon open doors for autistic IT professionals

CIO Business Intelligence

As one of the first partners of ATI, the biotechnology company hired interns to form a team of data stewards to work on a significant data segmentation project. The interns were specifically responsible to verify the accuracy and reliability of data, working alongside the team to ensure they adhere to compliance and regulatory policies.

Training 264
article thumbnail

Sana Biotechnology cuts the ribbon at new manufacturing facility near Seattle

GeekWire

Sana Biotechnology CEO Steve Harr cuts the ribbon at the company’s new manufacturing facility in Bothell, Wash., Sana Biotechnology CEO Steve Harr outside the company’s new manufacturing facility in Bothell, Wash., Washington state Rep. on Friday at a ribbon-cutting ceremony.

article thumbnail

Seattle startup Oisín Biotechnologies raises $15M to develop therapies for age-related diseases

GeekWire

Oisín Biotechnologies , a Seattle-based startup focused on treating aging-related diseases, raised $15 million in a Series A round led by AbbVie Ventures. The company is developing preclinical therapies to eliminate unwanted fat cells and build muscle mass to address frailty.

article thumbnail

Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more

GeekWire

Adaptive Photo) — Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies , the company said today in a regulatory filing. Sana Biotechnology named two new research leaders. Mark Adams. Adams joined the Seattle-based biotech giant more than three years ago.

article thumbnail

Sana Biotechnology boosts IPO range, looks to raise $517 million

GeekWire

Sana Biotechnology — the Seattle upstart that’s looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall Street. That would net the biotechnology company $517 million if it sold at the midpoint of that range. Sana’s technology (screen grab via IPO filing).